BERTEA CONSTRUCTION LTD

Company number 15022758 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

BERTEA CONSTRUCTION LTD - Analysis Report

Company Number: 15022758

Analysis Date: 2025-07-20 11:42 UTC

Financial Health Assessment for BERTEA CONSTRUCTION LTD (formerly MARIO IOSIF LTD)


1. Financial Health Score:

Grade: D (At Risk)
Explanation: The company’s financials show significant distress signals with negative net assets and a working capital deficit. While the business is newly incorporated and has minimal operating history, the current financial position indicates challenges in liquidity and solvency that require urgent attention.


2. Key Vital Signs:

Metric Value (£) Interpretation
Current Assets 69 Extremely low cash and short-term assets
Current Liabilities 6,773 Short-term debts exceeding current assets
Net Current Assets (Working Capital) -6,704 Negative working capital indicates liquidity stress
Total Net Assets -6,704 Company is insolvent on a balance sheet basis
Shareholders’ Funds -6,705 Equity is completely eroded; company is in deficit
Number of Employees 0 No staff employed yet; likely pre-revenue stage
Company Age ~1 year Start-up phase with limited operating history
Director Ownership 75-100% by Catalina Iosif Single controlling shareholder/director

Interpretation of Vital Signs:
The company’s "vital signs" indicate symptoms of financial distress. The negative working capital means the company currently owes more in short-term liabilities than it holds in liquid assets, which can impede day-to-day operations. Negative net assets show that the accumulated losses (or liabilities) outweigh the company’s resources, akin to an "unhealthy balance sheet." The absence of employees and early stage of the company suggest it is still in its infancy, possibly pre-trading or early trading with initial losses.


3. Diagnosis:

  • Liquidity Deficiency: The company’s extremely low cash of £69 against creditors of £6,773 signals a cash flow "blockage." This "symptom" suggests the company may struggle to meet immediate financial obligations without additional capital or credit support.
  • Capital Structure Fragility: The shareholders’ deficit of £6,705 means the business has consumed all its equity and more, putting it in a technically insolvent state on accounting grounds. This is like a patient with a weakened immune system, vulnerable to financial shocks.
  • Early-stage Business Status: Given incorporation in July 2023 and no employees, the company is likely in a start-up or set-up phase, which can explain losses and negative equity due to initial investment, pre-revenue expenses, or funding delays.
  • Related Party Creditors: The £6,773 short-term liabilities include director loans (£1,143) and amounts owed to a related party (£5,630). This may indicate reliance on internal funding to finance operations, which is common in start-ups but creates risk if not converted to equity or repaid timely.

Overall, the company shows clear "symptoms of financial distress," particularly liquidity and solvency issues, but as a very young entity, this may reflect start-up phase challenges rather than chronic illness.


4. Recommendations:

  • Improve Liquidity: Seek immediate infusion of cash either through shareholder loans, equity funding, or business loans to bolster working capital. This is like administering IV fluids to stabilize a dehydrated patient.
  • Convert Loans to Equity: Consider converting director or related party loans into equity to improve the balance sheet and reduce short-term pressure. This strengthens "capital resilience."
  • Develop a Cash Flow Forecast: Implement detailed cash flow planning to anticipate funding needs and avoid liquidity crises. Early detection of cash flow gaps can prevent emergencies.
  • Operational Launch and Revenue Generation: If not already commenced, focus on starting trading activities to generate cash inflow and reduce dependency on loans. Increasing revenues is akin to strengthening the patient’s immune response.
  • Cost Control and Budgeting: Monitor and control expenses tightly given limited resources to avoid exacerbating losses. Avoid unnecessary costs while the company builds operational momentum.
  • Regular Financial Review: Maintain timely preparation and review of management accounts to detect financial "symptoms" early and adjust strategy accordingly.
  • Explore External Funding Options: Consider grants, start-up loans, or external investors to diversify funding sources and improve financial stability.

Executive Summary

Perspective: Financial Health Diagnostician · Model: gpt-4.1-mini · Generated 20 July 2025

Sign in to generate a free AI analysis of this company — no password needed, just an email link.